Related Experiment Video
Updated: Jun 26, 2026
11:34
Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity
Published on: January 10, 2013
Dopamine agonist monotherapy in Parkinson's disease
1Department of Neurology, University of Birmingham, Birmingham, UK. c.e.clarke@bham.ac.uk
Lancet (London, England)
|December 14, 2002
Summary
Dopamine agonist monotherapy may slow Parkinson's disease progression compared to levodopa, but further research is needed for definitive guidance on treatment strategies.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Levodopa is the standard Parkinson's disease treatment but causes motor complications and may be neurotoxic.
- Dopamine agonists are increasingly used as initial monotherapy, but their long-term effects and potential neuroprotective properties are debated.
- Advanced imaging techniques like PET and SPECT tracers offer insights into dopaminergic neuron integrity.
Purpose of the Study:
- To evaluate the potential neuroprotective effects of dopamine agonist monotherapy versus levodopa in early Parkinson's disease.
- To compare the rate of dopaminergic neuron loss using imaging biomarkers in patients treated with agonists or levodopa.
- To review the clinical evidence regarding the efficacy, safety, and quality of life associated with agonist versus levodopa therapy.
Main Methods:
- Randomized controlled trials comparing dopamine agonists (pramipexole, ropinirole) with levodopa in early Parkinson's disease patients.
- Utilized 123I-beta-CIT SPECT and 18F-DOPA PET imaging to assess striatal dopaminergic neuron integrity.
- Analyzed clinical outcomes including motor function, involuntary movements, adverse events, and quality of life.
Main Results:
- SPECT and PET studies indicated significantly reduced loss of striatal uptake in patients treated with pramipexole or ropinirole compared to levodopa.
- Agonist monotherapy delayed the onset of involuntary movements but resulted in poorer motor control and more adverse events.
- Quality of life data showed no significant difference between pramipexole and levodopa after four years, with agonists being more expensive.
Conclusions:
- Evidence suggests dopamine agonist monotherapy may offer neuroprotection or that levodopa is neurotoxic, though methodological criticisms exist.
- Current data support agonist monotherapy for younger Parkinson's patients at risk of motor complications.
- For most patients, clear guidance is lacking, and large-scale, long-term pragmatic trials are essential to determine optimal treatment strategies.
More Related Videos
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications